BBK Holdings opens European subsidiary to support clinical trials

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/themotioncloud)
(Image: Getty/themotioncloud)

Related tags: Clinical trials, Clinical data, Patient centricity, Clinical trial, Patient recruitment, GDPR, Brexit

BBK Holdings, parent company of BBK Worldwide, has established BBK Patient Experience Limited to support patient data protection in clinical trials and add to its footprint in the EU.

BBK Holdings parent company of BBK Worldwide announced the building of additional subsidiary in the EU BBK Patient Experience Limited located in Dublin, Ireland to support the company’s reimbursement programs to increase access to care while supporting data protection initiatives.

Joan Bachenheimer, founding principal and CEO of BBK Worldwide told us that establishing this subsidiary in the EU served a twofold purpose. It will facilitate requirements for international banking organizations, and support data protection mandated by the European Union’s General Data Protection Regulation (GDPR​).

“This was the most logical move in order to not only be able to respond quickly to the shifting global landscape but to ensure we provide patients with the services they need for a positive clinical trial experience,”​ Bachenheimer added.

GDPR applies not only to EU organizations but also located outside of Europe that provides goods or services to citizens in the region.

BBK’s technology-based reimbursement and travel programs, RSG Card and RSG Arrive, were launched in 2013. Bachenheimer told us that reimbursement​ is important in clinical trials as it removes barriers to patient participation and removes administrative tasks from the site. The company released a report stated that 40% of patients said travel assistance would have been helpful in the clinical trial experience.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more